Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting ( NEW YORK--(BUSINESS WIRE)--Jun 5 2007 ...)

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuximab), the first approved IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) developed and commercialized by ImClone Systems Incorporated, was the focus of nine oral and 46 poster presentations at the recently concluded 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

This year's ASCO ERBITUX presentations showcased the extensive clinical development of ERBITUX reporting Phase I through Phase III clinical trial results in a broad range of cancers, including colorectal, head and neck, non-small cell lung, pancreatic, gastric, hepatocellular (liver), brain and ovarian cancer.

"We are very pleased with the extensive ERBITUX data that was presented at ASCO. These findings should expand treatment options for patients with cancer," said Alexander J. Denner, Ph.D., Chairman of ImClone System's Executive Committee. "The data continue to validate the IgG1 monoclonal antibody platform upon which the ImClone product pipeline is based."

Colorectal Cancer Highlights

Results from three Phase III studies (CRYSTAL, EPIC and NCIC CO.17) discussed during oral presentations provide important evidence of the clinical benefits demonstrated with ERBITUX treatment across the continuum of care in metastatic colorectal cancer. These three studies demonstrate significant improvements in 1st, 2nd and refractory mCRC patient outcomes including overall survival, survival without disease progression, tumor shrinkage and improvements in patient quality of life versus various standards of care.

The Phase III CRYSTAL study, conducted by Merck KGaA, of ERBITUX plus FOLFIRI (an irinotecan-based chemotherapy) in 1198 patients with previously untreated metatstatic colorectal cancer (mCRC) achieved its primary end point of improved survival without disease progression - decreasing the risk of disease progression by
'"/>

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:

( NEW YORK--(BUSINESS WIRE)--Jun 5 2007 ...)Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting,Health